Skip to search formSkip to main contentSkip to account menu

Lurbinectedin

A synthetic tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogue with potential antineoplastic activity. Lurbinectedin covalently binds… 
National Institutes of Health

Related topics

Related topics

7 relations
DNADNA CrosslinkingDNA IntercalationDNA Synthesis Inhibition

Narrower (1)

PM 01183

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Pooled safety analysis of single-agent lurbinectedin versus topotecan (Results from a randomized phase III trial CORAIL and a phase II basket trial).
3635Background: Lurbinectedin (L), an inhibitor of active transcription, has shown activity in second-line (2L) small cell lung… 
2018
2018
Efficacy and safety of lurbinectedin (PM1183) in small cell lung cancer (SCLC): Results from a phase 2 study.
8570Background: SCLC is a deadly cancer and despite initial 80% response, almost all patients (pts) will relapse and die of this… 
2018
2018
ATLANTIS: Global, randomized phase III study of lurbinectedin (L) with doxorubicin (DOX) vs. CAV or topotecan (T) in small-cell lung cancer after platinum therapy.
TPS8587Background: Lurbinectedin (L), a synthetic analog of marine-based tetrahydroisoquinolone, blocks active transcription… 
2018
2018
Efficacy and safety of lurbinectedin (PM1183) in Ewing sarcoma: Final results from a phase 2 study.
11519Background: Patients (pts) with relapsed Ewing sarcoma (ES) have a poor outcome. New therapeutic agents are needed. L is a… 
2018
2018
Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial.
Review
2017
Review
2017
Activity of lurbinectedin (PM01183) as single agent and in combination in patients with endometrial cancer
5586Background: Lurbinectedin (L) is a new anticancer drug that blocks trans-activated transcription, induces DNA double-strand… 
2016
2016
CORAIL trial: Randomized phase III study of lurbinectedin (PM01183) versus pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with platinum-resistant ovarian cancer.
TPS5597Background: PM01183 (PM; lurbinectedin) is a new anticancer drug that blocks trans-activated transcription, induces DNA… 
2016
2016
Abstract 1284: Lurbinectedin reduces tumor-associated macrophages and the production of inflammatory cytokines, chemokines, and angiogenic factors in preclinical models
Lurbinectedin, currently undergoing clinical evaluation in ovarian, breast and small-cell lung cancer patients, inhibits active… 
2015
2015
Abstract P3-13-01: Lurbinectedin (PM01183) activity in BRCA1/2-associated or unselected metastatic breast cancer. Interim results of an ongoing phase II trial
Background: Metastatic breast cancer (MBC) is a clinically heterogeneous disease in which selective approaches are needed to… 
2015
2015
Lurbinectedin (PM01183) with doxorubicin (DOX), an active treatment as second-line therapy in small cell lung cancer (SCLC).
7509 Background: PM01183 inhibits transactivated transcription and acts on the tumor microenvironment. It lacks cross-resistance… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)